Feasibility of first line nilotinib plus Peginterferon-α2b in chronic phase of chronic myeloid leukemia (CML): Results of the pilot phase of the German CML V (TIGER)-study

Authors
Category Primary study
ConferenceOncology Research and Treatment
Year 2015
This article has no abstract
Epistemonikos ID: 08244ded0b2739580adb53a2fdcb01b1b62c61b2
First added on: Apr 30, 2026